CD274 and neoplasm: In melanoma, it has been found that exosomal PD-L1 levels are associated with the tumour burden and immunotherapy sensitivity after patients receive PD-1 inhibitors, indicating the potential role of exosomal PD-L1 as a predictive biomarker for anti-PD-1 therapy.